Incretin Effect (GLP-1)

The classic experiment

The discovery is almost embarrassingly simple. Give a person a measured dose of glucose to drink and watch their insulin climb. On a separate day, infuse glucose into a vein at exactly the rate needed to reproduce the same blood glucose curve — bypassing the gut entirely. The blood sugar traces overlap, but the insulin response does not. The oral arm releases far more insulin. In healthy adults, that gap — the incretin effect — accounts for somewhere between 50 and 70 percent of the total insulin secreted after a meal.

The conclusion is unavoidable: something about glucose passing through the gut, not just appearing in the blood, tells the pancreas to release insulin. That something is a set of gut hormones — the incretins. The word itself, coined in the 1930s and revived in the 1960s, fuses "intestine" with "secretion of insulin." The gut is acting as an endocrine organ, anticipating the glucose load and warning the beta cell before the tide of sugar fully arrives.

The two incretins: GLP-1 and GIP

Two hormones do nearly all of this work. Glucose-dependent insulinotropic polypeptide (GIP), a 42-amino-acid peptide, is released by K cells in the duodenum and proximal jejunum. Glucagon-like peptide-1 (GLP-1), a smaller peptide cleaved from the proglucagon gene, is released by L cells concentrated in the distal small intestine and colon. Both are secreted within minutes of nutrients — glucose, fat, and amino acids — reaching the gut lumen, with circulating levels rising and the early peak appearing within roughly 15 to 30 minutes of eating.

Both bind G-protein-coupled receptors on the pancreatic beta cell and raise intracellular cyclic AMP, which potentiates the insulin-release machinery. The defining feature is right there in GIP's name: this potentiation is glucose-dependent. When blood glucose is low, the incretins barely nudge insulin secretion. When glucose is high, they amplify it dramatically. This safety valve is why GLP-1-based therapy rarely causes hypoglycemia by itself — there is no insulin push without a glucose signal to ride on.

GLP-1 does considerably more than GIP, and this breadth is why it became the more important drug target:

• Amplifies insulin secretion from beta cells in a glucose-dependent way.
• Suppresses glucagon from pancreatic alpha cells, cutting the liver's glucose output. (GIP, notably, tends to raise glucagon — a key difference between the two.)
• Slows gastric emptying, flattening the post-meal glucose spike by metering food into the intestine more gradually.
• Promotes satiety by acting on the hypothalamic arcuate nucleus and the brainstem, reducing food intake.
• Supports beta-cell health in preclinical models, enhancing insulin gene expression and beta-cell survival.

The DPP-4 brake

Native GLP-1 is almost comically short-lived. The enzyme dipeptidyl peptidase-4 (DPP-4) — present on endothelial cell surfaces and circulating in plasma — clips the first two amino acids off the N-terminus of GLP-1 and GIP, producing inactive fragments. It does this fast: the active half-life of GLP-1 is under two minutes, and most of a secreted GLP-1 pulse is degraded before it even leaves the gut capillary bed. What reaches the systemic circulation and the pancreas is a small fraction of what the L cells released.

This rapid breakdown is the single biggest obstacle to using GLP-1 therapeutically, and the entire pharmacology of the field is built around defeating it. Two strategies emerged. The first blocks the enzyme: DPP-4 inhibitors (the "gliptins" — sitagliptin, linagliptin, saxagliptin) prevent GLP-1 and GIP degradation, roughly doubling endogenous active incretin levels. The second resists the enzyme: GLP-1 receptor agonists are engineered peptides whose structure DPP-4 cannot cleave, extending the half-life from minutes to hours (exenatide, liraglutide) or even a full week (once-weekly semaglutide). Both raise GLP-1 signaling; they differ in magnitude and in whether glucagon suppression and weight loss are pronounced.

The blunted incretin effect in type 2 diabetes

In type 2 diabetes the incretin effect collapses from its healthy 50-70 percent down to roughly 20-30 percent of the insulin response. For decades this was assumed to mean the gut had stopped making incretins. The reality is more specific. GLP-1 secretion is only modestly reduced, and crucially, the beta cell's response to GLP-1 is largely preserved — which is precisely why giving more GLP-1 pharmacologically still works. The dominant lesion is GIP resistance: the diabetic beta cell stops responding to GIP almost entirely, even though GIP continues to circulate at near-normal levels. Because GIP normally supplies a large share of the incretin response, losing its effect tanks the overall number.

Whether this blunting is a cause or a consequence of hyperglycemia is still argued; chronic high glucose appears to itself impair GIP signaling, suggesting a vicious cycle. But the practical implication is clear and has reshaped diabetes care: restore the incretin signal pharmacologically and you can recover a large part of the lost insulin response, lower glucagon, slow the stomach, and reduce appetite — all at once. The newest agents go further. Tirzepatide is a dual GIP/GLP-1 receptor agonist that, by activating GIP receptors with a high-dose synthetic agonist, appears to overcome some of the GIP resistance and produces both glycemic control and weight loss exceeding GLP-1 alone (around 20 percent body weight in trials).

Oral vs. intravenous glucose — the same sugar, two responses

The table below makes the core experiment concrete. Both routes raise blood glucose identically by design; everything downstream differs.

Feature	Oral glucose	Intravenous glucose (matched)
Blood glucose curve	Reference	Titrated to match exactly
Passes through gut lumen	Yes — contacts L and K cells	No — bypasses the intestine
GLP-1 / GIP released	Yes, within minutes	No incretin release
Insulin secreted	High (baseline + incretin boost)	Lower — direct glucose stimulation only
Incretin contribution (healthy)	~50-70% of the response	0% (no incretin signal)
Glucagon	Suppressed by GLP-1	Less suppressed
Gastric emptying / satiety effects	Present (GLP-1-mediated)	Absent

Clinical correlations

• Type 2 diabetes. GLP-1 receptor agonists and DPP-4 inhibitors are now mainstays. The agonists additionally reduce cardiovascular events and slow kidney disease progression in high-risk patients, benefits that go beyond glucose lowering.
• Obesity. Semaglutide 2.4 mg and tirzepatide are approved for weight management in people without diabetes, producing 15-20 percent average weight loss — figures that approach bariatric surgery for some patients.
• Post-bariatric physiology. Roux-en-Y gastric bypass routes nutrients rapidly to the distal gut, dramatically increasing GLP-1 secretion. This exaggerated incretin response helps explain why diabetes often remits within days of surgery, before significant weight is lost.
• Reactive hypoglycemia / dumping syndrome. The same post-bypass GLP-1 surge can, in some patients, drive excessive late insulin release and symptomatic hypoglycemia after meals.
• Anesthesia and aspiration risk. Because GLP-1 agonists slow gastric emptying, retained stomach contents have prompted updated pre-operative fasting and airway guidance for patients on these drugs.
• Gut-brain signaling. The satiety arm of GLP-1 has opened research into addiction, NASH/MASH liver disease, and neurodegeneration, where GLP-1 receptors in the brain are being actively studied.

Common misconceptions

• "GLP-1 lowers blood sugar like insulin." GLP-1 does not move glucose into cells. It tells the beta cell to release more of its own insulin, and only when glucose is high.
• "Incretin drugs cause hypoglycemia." On their own they rarely do, because the insulin boost is glucose-dependent. The risk appears mainly when combined with insulin or sulfonylureas.
• "The incretin effect is gone in diabetes because the gut stops making GLP-1." GLP-1 secretion is only modestly reduced; the bigger problem is the beta cell becoming resistant to GIP.
• "GIP and GLP-1 do the same thing." Both boost insulin, but GLP-1 suppresses glucagon while GIP tends to raise it — and only GLP-1 strongly slows the stomach and curbs appetite.
• "Weight loss from GLP-1 drugs is just nausea." Some early intake reduction is gastrointestinal, but the durable effect is central — real reduction in hunger and food reward signaling.
• "DPP-4 inhibitors and GLP-1 agonists are interchangeable." Gliptins only raise your own modest GLP-1 levels and are weight-neutral; agonists deliver supraphysiologic signaling and drive weight loss.

This article is educational and is not medical advice. Decisions about diabetes or weight-loss medication should be made with a qualified clinician.